US 12,006,551 B1
MiRNA marker for diagnosis and/or treatment of alzheimer's disease
Rui Liu, Beijing (CN); Zhuorong Li, Beijing (CN); Li Zeng, Beijing (CN); Ting Sun, Beijing (CN); Mimin Liu, Beijing (CN); and Junxia Zhang, Beijing (CN)
Assigned to Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking University, Beijing (CN)
Filed by INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE, Beijing (CN)
Filed on Jul. 15, 2022, as Appl. No. 17/865,475.
Application 17/865,475 is a continuation of application No. 17/614,414, previously published as PCT/CN2020/084626, filed on Apr. 14, 2020.
Claims priority of application No. 201911078320.8 (CN), filed on Nov. 6, 2019.
Int. Cl. C12Q 1/682 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/686 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/178 (2013.01)] 1 Claim
 
1. A method for treating a mouse with Alzheimer's disease (AD), comprising injecting adeno-associated virus (AAV) carrying hsa-miR-23b into the mouse with Alzheimer's disease (AD), wherein the hsa-miR-23b consists of SEQ ID NO: 1.